• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Podcast: CEO Brian Concannon on the past and future for Haemonetics at MassDevice.com’s DeviceTalks

Podcast: CEO Brian Concannon on the past and future for Haemonetics at MassDevice.com’s DeviceTalks

July 23, 2014 By Brian Johnson

More than a year ago, Haemonetics (NYSE:HAE) launched a major restructuring effort, moving nearly 300 manufacturing jobs out of the country in an effort to cut between $35 million and $40 million by fiscal 2018.

The cuts were painful, not only for the 42-year-old blood management company and its workers, but for CEO Brian Concannon, who grew up only a stone’s throw from the company’s headquarters in Braintree, Mass.

Speaking at MassDevice.com‘s DeviceTalks Boston event last week, Concannon said it was a "real challenge" for a guy with strong local roots to cut jobs in his back yard.

"We really needed to understand what we were going to do tomorrow differently than what we’re doing today, because we had to invest differently for our future," Concannon told us. "It was grounded in doing what was right for our customers, our employee base and what was right for shareholders.

"You can do the right thing for the company, but it doesn’t mean you can’t do the right thing by the people who are affected in a negative way through this process," he said.

Haemonetics took the unusual step of providing up to 18 months’ notice to the affected workers, something Concannon said went against the accepted wisdom.

"A lot of people will say, ‘That’s a dumb thing to do and you shouldn’t do that because you die a slow death,’" he said. "But we’ve received good responses from our employees."

Over the past year, he added, the company has worked hard to re-train workers hit by the cuts, providing assistance with everything from English-as-a-2nd-language classes to bringing in potential new employers to interview workers at Haemonetics’ South Shore headquarters.

Concannon said the results speak for themselves.

"The most amazing thing is, 1 month into the transition, the productivity at our Braintree headquarters was higher than when we started," he said.

Conconnan opened up about the cuts and more in this 35-minute interview, recorded July 15, 2014, as part of our DeviceTalks series. Stay tuned for more details on our upcoming event in Orange County, Calif., this December.

Filed Under: Blood Management, Device Talks Podcasts, News Well Tagged With: Haemonetics, MassDevice.com, Podcast/Feature Tease

More recent news

  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke
  • Carlsmed launches IPO roadshow
  • Varian introduces IntelliBlate for image-guided cancer therapy in Europe
  • Henry Schein CEO Stanley M. Bergman to retire

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy